Exam 1 Flashcards
The easiest kind of data to acquire to use to identify population health issues is which of the following?
A. claims data
B. EHR data
C. satisfaction survey data
D. medication adherence data
E. socioeconomic data
A. claims data
According to Health People 2020 data, the access to health services is not impacted by family income.
T/F
False
In 2020, the leading cause of mortality for children ages 1-19 in the US was which of the following?
A. Cancer
B. Motor vehicle accidents
C. heart disease
D. firearms
E. congenital disorders
D. Firearms
Life expectancy, maternal mortality, and infant mortality data in the US is superior to most other industrialized nations in the world.
T/F
False
Costs of pain and suffering are examples of intangible costs and are difficult to measure
T/F
True
A cost-minimization analysis is only useful when the outcomes are equal
T/F
True
Which of the following is not an example of direct medical costs?
A. medications
B. lab tests
C. travel costs to hospital or clinic
D. provider charges
E. hospital charges
C. travel costs to hospital or clinic
A cost-effectiveness analysis is commonly used to compare a new treatment to a standard treatment.
T/F
True
When comparing two therapeutic agents in a pharmacoeconomic analysis, all costs associated with the drug (not just acquisition cost) should be taken into account.
T/F
True
Which of the following types of PE analysis is used when you want to measure the quality of outcome produced and is usually measured in quality-adjusted life year
A. cost-benefit analysis
B. cost-minimization analysis
C. cost-utility analysis
D. cost-effectiveness analysis
C. cost-utility analysis
Which of the following is NOT a surrogate endpoint that is used to evaluate the potential benefits of using tirzepatide to treat patients with DM?
A. reduction in CV mortality
B. Hgb A1c
C. weight loss/BMI
D. fasting blood glucose
A. reduction in CV mortality
The study of the utilization and effects of drugs in large numbers of people is best defined as:
A. pharmacovigilance
B. comparative effectiveness research
C. pharmacoepidemiology
D. pharmacoeconomics
C. pharmacoepidemiology
Which of the following is least likely to identify how a drug or therapy will perform in real world settings.
A. randomized controlled trials
B. comparative effectiveness research
C. pragmatic clinical trials
A. randomized controlled trials
Pharmacovigilance studies are used to identify undetected ADRs or safety-related aspects of marketed drugs not observed in pre-marketing studies.
T/F
True
Pharmacoepidemiologic and pharmacovigilance studies are primarily:
A. experimental
B. non-experimental (observational)
C. neither of the above
B. non-experimental (observational)
A typical randomized controlled trial may determine the efficacy of a drug but may not determine if the drug will achieve its desired effect in a real-world setting.
T/F
True
RCTs have a higher degree of external validity than do pragmatic trials
T/F
False
Pharmacovigilance studies typically use observational data from a single database from a small targeted population.
T/F
False
Which of the following complications associated with use of fluoroquinolones was teased out from data in post-marketing pharmacovigilance studies:
A. blood dyscrasias
B. electrolyte abnormalities
C. disabling peripheral neuropathies/myopathies
D. skin rash
C. disabling peripheral neuropathies/myopathies
The US spend significantly more money than other comparable on healthcare but achieves poorer outsomes.
T/F
True
Retail prescription drug constitute the largest share (as a percentage) of all categories associated with national health expenditures.
T/F
False